Bhavik P Shah, Patrick M Sleiman, Jessica Mc Donald, Ida H Moeller, Patrick Kleyn
{"title":"Functional characterization of all missense variants in <i>LEPR, PCSK1</i>, and <i>POMC</i> genes arising from single-nucleotide variants.","authors":"Bhavik P Shah, Patrick M Sleiman, Jessica Mc Donald, Ida H Moeller, Patrick Kleyn","doi":"10.1080/17446651.2023.2179985","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Hyperphagia and early-onset, severe obesity are clinical characteristics of rare melanocortin-4 receptor (MC4R) pathway diseases due to loss-of-function (LOF) variants in genes comprising the MC4R pathway. In vitro functional characterization of 12,879 possible exonic missense variants from single-nucleotide variants (SNVs) of <i>LEPR, POMC</i>, and <i>PCSK1</i> was performed to determine the impact of these variants on protein function.</p><p><strong>Methods: </strong>SNVs of the three genes were transiently transfected into cell lines, and each variant was subsequently classified according to functional impact. We validated three assays by comparing classifications against functional characterization of 29 previously published variants.</p><p><strong>Results: </strong>Our results significantly correlated with previously published pathogenic categories (r = 0.623; <i>P</i> = 3.03 × 10<sup>-4</sup>) of all potential missense variants arising from SNVs. Of all observed variants identified through available databases and a tested cohort of 16,061 patients with obesity, 8.6% of <i>LEPR</i>, 63.2% of <i>PCSK1</i>, and 10.6% of <i>POMC</i> variants exhibited LOF, including variants currently classified as a variant of uncertain significance (VUS).</p><p><strong>Conclusions: </strong>The functional data provided here can assist in the reclassification of several VUS in <i>LEPR, PCSK1</i>, and <i>POMC</i> and highlight their impact in MC4R pathway diseases.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"209-219"},"PeriodicalIF":2.7000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2023.2179985","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 1
Abstract
Objective: Hyperphagia and early-onset, severe obesity are clinical characteristics of rare melanocortin-4 receptor (MC4R) pathway diseases due to loss-of-function (LOF) variants in genes comprising the MC4R pathway. In vitro functional characterization of 12,879 possible exonic missense variants from single-nucleotide variants (SNVs) of LEPR, POMC, and PCSK1 was performed to determine the impact of these variants on protein function.
Methods: SNVs of the three genes were transiently transfected into cell lines, and each variant was subsequently classified according to functional impact. We validated three assays by comparing classifications against functional characterization of 29 previously published variants.
Results: Our results significantly correlated with previously published pathogenic categories (r = 0.623; P = 3.03 × 10-4) of all potential missense variants arising from SNVs. Of all observed variants identified through available databases and a tested cohort of 16,061 patients with obesity, 8.6% of LEPR, 63.2% of PCSK1, and 10.6% of POMC variants exhibited LOF, including variants currently classified as a variant of uncertain significance (VUS).
Conclusions: The functional data provided here can assist in the reclassification of several VUS in LEPR, PCSK1, and POMC and highlight their impact in MC4R pathway diseases.
期刊介绍:
Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.